Whatever Happened to Up-Front Equity?
Executive Summary
In the past, in-licensers of biotech products often turned to up-front equity purchases, rather than cash licensing payments, to help defray P&L costs of licensing. The partner received the same money to fund its research, the rationale went, and the licensee could book at least some of the payment as the acquisition of an asset, rather than an R&D expense. But as In Vivo amply demonstrates, that thinking is so 20th Century. While equity payments often made up more than half the total paid up front in biotech licensings throughout the 1990's, they've fallen to 25% or below, since 2002.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.